Format

Send to

Choose Destination
Rheum Dis Clin North Am. 2017 Aug;43(3):467-480. doi: 10.1016/j.rdc.2017.04.010.

Drug Repositioning Strategies for the Identification of Novel Therapies for Rheumatic Autoimmune Inflammatory Diseases.

Author information

1
AMPEL BioSolutions and RILITE Research Institute, 250 West Main Street, Suite 300, Charlottesville, VA 22902, USA. Electronic address: amriegrammer@comcast.net.
2
AMPEL BioSolutions and RILITE Research Institute, 250 West Main Street, Suite 300, Charlottesville, VA 22902, USA.

Abstract

Rheumatic Autoimmune Inflammatory Diseases such as Sjögren's and lupus lack modern treatments. Less than 5% of drugs approved by the FDA from 2014 to mid-2016 had a RAID indication. Many RAID standard-of-care drugs were repurposed based on serendipitous observations, similarity-of-disease categorization, and/or off-target effects. Recently, drug repurposing has become more intentional, relying on an evolving awareness of molecular underpinnings, as well as a better understanding of drug-target interactions by computational modeling. Understanding mechanisms of disease pathogenesis can be synergistic in identifying new drug candidates and target pathways using unbiased Big-Data repositioning approaches as genomics, PheWAS (disease mechanism-of-action), GWAS and/or epigenetic-profiling.

KEYWORDS:

Bioinformatics; Drug repositioning; Drug repurposing; Lupus; Rheumatic autoimmune inflammatory disease (RAID); SLE

PMID:
28711146
DOI:
10.1016/j.rdc.2017.04.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center